Q4 2025 · 13F-HR
Boxer Capital Management, LLCholdings as filed
Filed 2026-02-17 · accession 0002018299-26-000006
$456.9M
Reported value
45
Positions
2025-12-31
Period end
The Brief · Boxer Capital Management, LLC · Q4 2025
AI · grounded in 13F
Boxer Capital Management, LLC established a new position in TNGX valued at $96.4M. The fund also initiated new stakes in RVMD and KOD, worth $31.9M and $31.8M respectively. Other new additions include KYMR at $25.6M and CELC at $22.4M. Total assets under management stand at $456.9M across 45 positions.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 87583X109 | TNGX | TANGO THERAPEUTICS INC | $96.4M | 21.1% | 10,876,219 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $31.9M | 6.97% | 400,000 | Common | SOLE |
| 50015M109 | KOD | KODIAK SCIENCES INC | $31.8M | 6.95% | 1,136,000 | Common | SOLE |
| 501575104 | KYMR | KYMERA THERAPEUTICS INC | $25.6M | 5.60% | 329,100 | Common | SOLE |
| 15102K100 | CELC | CELCUITY INC | $22.4M | 4.91% | 225,000 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $16.9M | 3.69% | 125,000 | Common | SOLE |
| 69366J200 | PTCT | PTC THERAPEUTICS INC | $15.2M | 3.33% | 200,000 | Common | SOLE |
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $15.2M | 3.32% | 375,000 | Common | SOLE |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $14.8M | 3.25% | 170,000 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $13.7M | 3.00% | 46,457 | Common | SOLE |
| M96088105 | URGN | UROGEN PHARMA LTD | $11.7M | 2.56% | 500,000 | Common | SOLE |
| 171757206 | CDTX | CIDARA THERAPEUTICS INC | $11.7M | 2.56% | 53,000 | Common | SOLE |
| 696389402 | PALI | PALISADE BIO INC | $11.3M | 2.47% | 4,799,875 | Common | SOLE |
| 03237H101 | AMLX | AMYLYX PHARMACEUTICALS INC | $9.7M | 2.12% | 800,000 | Common | SOLE |
| 86889P208 | SRZN | SURROZEN INC | $9.4M | 2.06% | 416,150 | Common | SOLE |
| 14070B309 | CAPR | CAPRICOR THERAPEUTICS INC | $9.4M | 2.05% | 325,000 | Common | SOLE |
| 60255C885 | BRD1EUR | MIND MEDICINE MINDMED INC | $8.0M | 1.75% | 598,500 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $8.0M | 1.75% | 225,000 | Common | SOLE |
| 76029N106 | REPL | REPLIMUNE GROUP INC | $7.3M | 1.60% | 750,000 | Common | SOLE |
| N90064101 | QURE | UNIQURE NV | $6.9M | 1.52% | 290,000 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $6.4M | 1.39% | 100,000 | Common | SOLE |
| 23256X407 | HELP | CYBIN INC | $5.8M | 1.28% | 715,000 | Common | SOLE |
| 74017N105 | PGEN | PRECIGEN INC | $5.7M | 1.26% | 1,375,000 | Common | SOLE |
| 21217B100 | CTNM | CONTINEUM THERAPEUTICS INC | $5.6M | 1.24% | 494,000 | Common | SOLE |
| G2545C104 | CBIO | CRESCENT BIOPHARMA INC. | $5.4M | 1.18% | 453,686 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $5.3M | 1.16% | 70,000 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $5.2M | 1.14% | 75,000 | Common | SOLE |
| 05338F306 | AVTX | AVALO THERAPEUTICS INC | $5.0M | 1.09% | 275,000 | Common | SOLE |
| 45773H409 | INO | INOVIO PHARMACEUTICALS INC | $4.2M | 0.92% | 2,420,122 | Common | SOLE |
| 91678A107 | UPB | UPSTREAM BIO INC | $4.1M | 0.89% | 150,000 | Common | SOLE |
| 92764N102 | VIR | VIR BIOTECHNOLOGY INC | $3.8M | 0.82% | 625,000 | Common | SOLE |
| 00534A102 | IVVD | INVIVYD INC | $3.7M | 0.81% | 1,500,000 | Common | SOLE |
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $3.6M | 0.79% | 275,000 | Common | SOLE |
| 803607100 | SRPT | SAREPTA THERAPEUTICS INC | $3.2M | 0.71% | 150,000 | Common | SOLE |
| 713317105 | PEPG | PEPGEN INC | $2.4M | 0.53% | 373,892 | Common | SOLE |
| 67080M103 | NRIX | NURIX THERAPEUTICS INC | $1.9M | 0.42% | 100,000 | Common | SOLE |
| 48576U205 | KPTI | KARYOPHARM THERAPEUTICS INC | $1.9M | 0.41% | 252,536 | Common | SOLE |
| 83422E204 | SLDB | SOLID BIOSCIENCES INC | $1.7M | 0.37% | 300,000 | Common | SOLE |
| 50180M108 | LBRX | LB PHARMACEUTICALS INC | $1.6M | 0.34% | 70,000 | Common | SOLE |
| 59935V107 | MIST | MILESTONE PHARMACEUTICALS IN | $1.3M | 0.29% | 666,666 | Common | SOLE |
| 185634201 | CLNN | CLENE INC | $1.2M | 0.26% | 199,737 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $329,460 | 0.07% | 20,400 | Common | SOLE |
| G9TY5A101 | ZURA | ZURA BIO LTD | $262,000 | 0.06% | 50,000 | Common | SOLE |
| 67080N119 | NUVB/WS | NUVATION BIO INC | $88,000 | 0.02% | 266,666 | Common | SOLE |
| 86889P117 | SRZNW | SURROZEN INC | $1,333 | 0.00% | 66,666 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.